Research and development in the global mice model industry is gathering momentum with the increasing occurrence of numerous chronic diseases worldwide. Due to their physiological similarities with the human body, including the mammalian features, mice also suffer from many of the same diseases. This is why mouse models are widely used in biomedical research and experimentation to study the behavioral patterns of the microorganisms causing these diseases.
Over the years, a large number of mouse-based models have been created and studied to target specific human diseases with the help of genetic engineering and selective breeding. It is estimated that the global mice model market size will surpass US$12.3 billion in terms of revenue by 2026, driven by the increasing demand for humanized mouse models.
Expanding scope in cancer and neurological research
Cancer and neurological disorders are among the most prevalent health conditions across the globe. In order to better study these diseases, numerous research studies have been conducted in recent years.
In December 2020, for instance, a team of researchers at Scripps Research had demonstrated a promising new strategy for the treatment of lymphoma, a type of cancer that affects the infection resisting cells of the immune system known as lymphocytes, using a mouse model. The new approach brought a major improvement in the ability of natural killer (NK) cells to kill lymphoma cells and not harm the healthy ones.
Another research study in mice during the same month revealed that the brain’s immune cells constantly monitor their neighborhood to detect overexcited nerve cells. The findings from the new study could help study neurological conditions such as Alzheimer’s diseases, seizures, and epilepsy more effectively.
In December 2020, AB Science SA had announced the results from its phase 2B/3 study aimed at assessing the effect and action of masitinib, a tyrosine-kinase inhibitor, in Alzheimer’s disease. The research trial, which included experiments in a transgenic mouse model of Alzheimer’s disease, indicated that masitinib could show promising results in the treatment of the disease.
R&D based on mice model amid COVID-19 pandemic
With the rapid spread of the coronavirus outbreak worldwide throughout the first two quarters of 2020, biomedical and biopharmaceutical research institutes have been working tirelessly in order to study the behavior of the virus and develop a much-needed vaccine or cure.
A research study was conducted by the University of Iowa in December 2020 to shed light on the loss of smell in COVID-19 patients. When the COVID-19 pandemic started spreading exponentially earlier this year, the team realized that a mouse-based model they had created a decade ago to study SARS might be the key to understanding the coronavirus and testing its potential treatments.
One of the particularly interesting findings of the study was that mice infected with the coronavirus lost their sense of smell, which had been observed in a vast majority of COVID-19 patients. The model helped open up the possibility of learning more about this observation and understanding the mechanism of why people lose their sense of smell. This in turn could help cure a large number of individuals.
Future trends in the global mice model industry will likely be driven by the ongoing advances in gene editing and genetic engineering technologies. In both developed and developing countries, the demand for humanized mice models and the increase consumption of personalized medicines will strengthen the market outlook significantly.